Award Number: DAMD17-02-1-0586

TITLE: Tumor-Secreted Autocrine Motility Factor (AMF): Casual Role in an Animal Model of Cachexia

PRINCIPAL INVESTIGATOR: John M. Chirgwin, Ph.D.

CONTRACTING ORGANIZATION: University of Virginia
Charlottesville, Virginia 22904

REPORT DATE: August 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE August 2004 3. REPORT TYPE AND DATES COVERED Annual (1 Aug 2003 - 31 Jul 2004)

4. TITLE AND SUBTITLE Tumor-Secreted Autocrine Motility Factor (AMF): Casual Role in an Animal Model of Cachexia

6. AUTHOR(S) John M. Chirgwin, Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Virginia Charlottesville, Virginia 22904 Email = jc3qb@virginia.edu

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited

13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) Cancer cachexia has three clinical features: 1) loss of appetite (anorexia), 2) nutritional mal-absorption, and 3) muscle and fat wasting caused by tumor-stimulated factors. This project focuses on muscle wasting. A number of factors have been proposed to cause cancer cachexia. Lack of progress in the area is unfortunate, given the tremendous benefit patients with advanced cancer would receive from effective treatment of cachexia to improve quality of life and postpone mortality. We proposed that autocrine motility factor (AMF) is released into the bloodstream from cancer sites and stimulates muscle wasting. In the second grant period we have now demonstrated that administration of recombinant AMF protein to mice results in a statistically significant loss of weight, compared to control treatment, in 24 hours. We are ready to test the species specificity of this response. We have also determined the molecular structure of the recombinant mouse protein. In the next and final research year will assess some of the molecular pathways activated in muscle by AMF, which could contribute to cachexia. These include activation of proteasomal muscle protein degradation via the Foxo transcription factors and P13 kinase pathways and alterations in the secreted regulators of muscle mass, IGF-1 and myostatin.

14. SUBJECT TERMS cancer cachexia, proteasome, muscle wasting, phosphogluco isomerase glucose 6-phosphate isomerase, autocrine motility factor

15. NUMBER OF PAGES 45

16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT Unclassified 18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified 19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified

20. LIMITATION OF ABSTRACT Unlimited
# Table of Contents

- Cover...........................................................................................1
- SF 298...........................................................................................2
- Table of Contents...........................................................................3
- Introduction....................................................................................4
- Body.............................................................................................5
- Key Research Accomplishments....................................................7
- Reportable Outcomes....................................................................8
- Conclusions................................................................................9
- References..................................................................................10
- Appendices................................................................................21
INTRODUCTION:

Update on cancer cachexia, August 2004. The previous (first annual) progress report provided an extensive update. We provide only information new since then. Substantial progress has been made to identify biochemical mechanisms leading to muscle wasting and atrophy, but there have been no substantive breakthroughs in development of new animal models of cachexia, identification of additional circulating factors responsible for the syndrome, or the development of novel patient treatments (Tisdale, 2003).

Biochemical mechanisms of cachexia have been explored in vivo and in vitro. It now appears that muscle wasting involves paracrine factors in the microenvironment surrounding muscle that regulate its overall activity, in particular insulin-like growth factor-1 (Glass, 2003) and the TGF-beta superfamily member myostatin, also known as GFD-8, which is a negative regulator of muscle mass. (Roth & Walsh, 2004). IGF-1 appears to stimulate the PI3 kinase/Akt signaling and Foxo transcription factor pathways (Lee et al, 2004; Stitt et al, 2004; Sandri et al, 2004). The same pathways appear to be activated during muscle wasting in response to multiple causes; so these are likely also to be activated during cancer-induced muscle wasting (Lecker et al, 2004). Myosin heavy chain is a major substrate for degradation in cachectic skeletal muscle (Acharyya et al, 2004).

Role of the proteasome. Skeletal muscle proteolysis in cachexia is probably due to increased activity through the proteasomal pathway, rather than via lysosomes or soluble sarcoplasmic proteases. Certain cancer treatments can either enhance or inhibit this muscle degradation pathway. Thus, cancer chemotherapy may alter cachexia in patients. Omega-3 fatty acids and other eicosanoids can regulate the activity of the proteasome, providing a biochemical rationale for the dietary treatment of cancer cachexia. It is not yet clear that activation of proteasomal degradation is the central or the only pathway for muscle wasting in cancer cachexia (Glass, 2003; Lecker, 2003), but this seems increasingly likely and may involve specific activation in muscle cells of the specific ubiquitin E3 ligases, atrogin and MuRF1 (Dehoux et al, 2004; Sachek et al, 2004).

This report described progress on our project (now in its second year) to establish whether autocrine motility factor/phosphoglucose isomerase is a systemic cachectic factor. It has been known for 50 years to be elevated in patients with advanced, metastatic breast cancer, and we previously observed that it was also elevated in the circulation of nude mice that were cachectic due to advanced breast cancer metastases restricted to bone.
BODY OF PROGRESS REPORT

Timetable: The award of this grant was made just as the Principal Investigator was moving from the University of Texas to the University of Virginia. Initial work was commenced upon arrival in Charlottesville Virginia in October 2002. A new research associate was recruited to work on this project, Ms. Lisa Wessner, who has learned all of the techniques specific to the project, which has now been active since January 1 of 2003. Thus, this progress report represents work carried out over a 12 month period from July 2003 to July 2004, and the report ends after 18 months of research have been carried out in total. The animal results reported below, although gratifyingly successful, were substantially delayed by a serious, documented outbreak of the lethal mouse pathogen *Burkholderia gladioli* (Foley et al, 2004) in our animal facility. This caused two problems. *Burkholderia* can be easily transmitted from regular lab mouse strains to immunocompromised ones. Under our quarantine conditions, animal handlers can only handle nude mice if they have been completely decontaminated after handling non-nudes. This is highly impractical, since a central part of our research involves growth of human tumor cells in nude mice, typically in 6-month experiments. The only practical solution to this problem has been to carry out ALL animal experiments in nudes. Our ultimately successful quarantine approach was to avoid initiation of all new animal experiments, while the source of the outbreak was determined and infected animals were identified and sacrificed. This took six months. Our animal experiments, shown below, have thus been delayed by six months. For this reason we have requested a one-year no-cost extension of funding to permit us to complete the remaining tasks. Thus, we anticipate filling the final progress report for this proposal in August 2005.

The revised application contained 3 Specific Aims and 9 Tasks in the revised Approved Statement of Work:(Revised 01/04/02 with original Aims 4 & 5 deleted):

**Task 1** (Aim 1) Determine dose range and Alzet mini-pump size for administration of mAMF to achieve effective blood levels of ~10ng/mL. [28 mice] Year 01, months 1-6.

**Task 2** (Aim 1) Demonstrate cachexia with mouse AMF infused into mice, compared to controls and to mice bearing CHO-K1 [mAMF-] and CHO-1C6 [mAMF+] IM tumors. [56 mice] Year 01, months 7-12.

**Task 3** (Aim 1) Carry out routine pathology and histology of animals from Task 2. Year 01, months 10-12.

**Task 4** (Aim 1) Determine host concentrations of 4 host cytokines in baseline and sacrifice blood samples of animals from task 2. Year 02, months 1-4.

**Task 5** (Aim 2) Construct two mutants of mAMF [E357A and 4S/T-A] and sequence. Year 02, months 1-4.

**Task 6** (Aim 2) Express and purify mutant mAMF proteins and determine Km and Vmax and binding to phosphocellulose. Year 02, months 5-8.
Task 7 (Aim 2) Carry out Task 2 & 3 protocols with wt & 2 mutant mAMFs by pump infusion. [24 mice] Year 01, months 9-2; Year 02, throughout.

Task 8 (Aim 3) Carry out Task 2 & 3 protocols with mouse versus 3 concentrations of human AMF. [40 mice] Year 02, months 1-12.

Task 9 (Aims 1-3) Analyze data, prepare and submit results for meeting presentations, progress reports, and peer-reviewed publication. Year 01-02, throughout.

Total mice requested = 148 [adult female Balb/c & Balb/c nudes, 32 mice were eliminated in deleted Aim 5]. All use of human cell lines and radioisotopes was eliminated with the deletion of Aims 4 & 5. Animal use has been reported separately to the DoD. Since the annual animal usage and progress reports cover different times, the most recent animal usage form did not include the mice that were used in Figures 1 and 2.

Progress:

Task 1 was completed in the first year.

Task 2 has been carried out in this report period. Previous experiments demonstrated that a simpler approach than originally proposed successfully gave substantially increased steady-state blood concentrations of mouse PGI/AMF. In this experimental protocol, animals were given the factor as sterile intraperitoneal (i.p.) injections of protein in PBS at 8 AM, noon, and 4 PM. Blood levels of PGI/AMF were measured at the 4PM time, and the animals were weighed. The injected mouse AMF/PGI was entirely cleared from the blood stream by 24 hours. Figures 1 and 2 show the result of a substantial animal experiment in which nude mice were injected 3 time per day for 3 days with 100 µl of sterile PBS containing purified mouse AMF/PGI (positive, shown in square symbols) or BSA (negative control) at either 150 or 500 µg of protein per dose. The experiment was carried out with Balb/C nu/nu mice and 5 or 10 mice per group. Statistical significance was determined by analysis of variance using the 2-way ANOVA facility plus post-test analysis of the GraphPad Prizm graphics program. The data demonstrate that 150 µg doses were ineffective to cause weight loss (Figure 1), while 500 µg doses (Figure 2) caused a statistically highly significant cachexia by 24 hours after the initial injection, which appeared to persist for 24hrs after the cessation of injection following three days of treatment.

Mouse AMF/PGI for these experiments was prepared in E coli and purified by NiNTA chromatography using the 6xHis C-terminal extension. As detailed in the first progress report, these recombinant protein preparations were carefully analyzed for contamination with bacterial endotoxin and determined to be free of this material to well below a level that would cause inflammation in the animals. The laboratory animal personnel report that the AMF/PGI treatments did not cause any apparent pain or discomfort to the mice.

On the basis of the results shown in Figures 1 and 2, the experiments for Tasks 3 and 4 will be carried out in the next funding period by direct i.p. injection of recombinant protein 3X per day at the dosage used for Figure 2. In addition to the routine histology proposed in task 3, we will assess whether a series of muscle genes are activated. Mice will be sacrificed at the end of the third day of treatment. Muscle RNA will be assayed by real-time PCR with mouse-
specific primer pairs for a series of markers discussed in the Introduction, above: IGF-1, myostatin, atrogin, MuRF-1, myosin heavy chain, and Foxo 3. We will also prepare muscle homogenates from treated and control mice and assay them for proteasomal activity (Reinheckel et al, 2000) as shown in Figure 3.

Tasks 5 and 6 have been completed. The catalytically inactive mutant E357A has been constructed, expressed and purified. In collaboration with Dr Christopher Davis at the University of South Carolina, the x-ray crystal structure of this mutant has been determined. The data were originally included in the manuscript submitted to J Mol Biol, now in press as Solomons et al (below under Research Accomplishments, but the data on the mutant were removed to keep the paper within acceptable page limits and will be submitted later. The role of isomerase (PGI) activity in relation to autocrine motility factor (AMF) activity remains controversial in the field. Much of the published AMF cytokine work has not taken into account the current knowledge of PGI structure. We (Davies et al, 2003) and others (Arsenieva & Jefferey, 2002), have shown that ligand binding to mammalian PGIs results in only very small conformational changes in the surface of the protein away from the active site (where binding to the AMF receptor almost certainly takes place). These conformational changes are almost certainly insufficient to have any effect on a receptor-mediated cytokine-like action of the protein. We believe that mouse E357A AMF/PGI will be active in the cachexia assay. This is proposed in Task 7, which will be carried out in the final funding period.

We are also ready to carry out Task 8, the cachexia model, by injecting mice with 500 μg/dose of human AMF/PGI. Our extensive preliminary data, presented previously, showed an approximately 100-fold species preference for mouse versus human factor acting on cells of the same versus the opposite species. We thus expect that this dose of the human protein will be without effect. 100X higher should be effective, but it is impractical both for the investigator and the mouse to repeat the experiment with 50 mg of purified protein per dose.

KEY RESEARCH ACCOMPLISHMENTS:

1) Purification of recombinant AMF/PGI with low endotoxin content finalized.

2) Animal model of direct i.p. injection of mouse AMF/PGI established in previous year successfully used to cause statistically significant (4%) weight loss in 24hrs compared to equivalent control protein treatment. Partial dose-response established between 450 (ineffective) and 1500 (effective) μg/mouse/day.

3) Human AMF/PGI prepared to carry out species-specific test of the results found in accomplishment 2) in 3rd (final) year.

4) Crystal structure of mouse AMF/PGI, used in all of the work for this proposal, solved and published.

5) In vitro assay for proteasome activation in mouse C2C12 myoblasts established and responses to mouse AMF/PGI demonstrated.
REPORTABLE OUTCOMES (since previous report):

Six manuscripts published, which include reviews of the contributions of bone metastases to cancer cachexia, while the sixth paper derives directly from the work carried out for this proposal:


Two manuscripts in press or accepted for publication, which include reviews of the contributions of bone metastases to cancer cachexia:


CONCLUSIONS

Purified mouse autocrine motility factor/phosphoglucone isomerase was found to cause statistically weight loss (cachexia) after 3 days of 3X daily intraperitoneal injection at a dose of 0.5 mg/injection, which was accompanied by significant increases in serum concentrations of the factor. This is a simpler animal model than originally proposed. Thus, the main hypothesis of the original proposal has been validated.

Progress in the second year has been fully successful but substantially delayed by a disease outbreak in the P.I.'s animal facility. Experiments for 2004 were delayed until June and July. We have requested and received a one-year no cost extension of the grant from the DoD and now plan to complete the work proposed by the end of July 2005.

Structures of the AMF/PGI proteins, including mouse and human proteins and the enzyme complexed with inhibitor have been solved by x-ray crystallography and published or accepted for publication. Mutant forms of the protein have been prepared. Experiments have been successfully completed to improve the purity of the recombinant protein and to characterize the effects of the factor on both intact animals and on a mouse muscle cell line in vitro. The structural data are now complete for analysis of the species-specific effects and their structural bases.
COMPREHENSIVE LIST OF REFERENCES:


Black K, Garrett IR, Mundy GR (1991). Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinol 128:2657-2659


Hasselgren PO, Wray C, Mammen J (2002). Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 290:1-10


Jagoe RT, Goldberg AL (2001). What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4:183-190


adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int J Cancer 87:574-581


Figure 1. In the experimental protocol, Balb/C nu/nu mice, approximately 25g in weight, were given the factor as sterile intraperitoneal (i.p.) injections of protein in PBS at 8 AM, noon, and 4 PM. Blood levels of PGI/AMF were measured at the 4 PM time. Animals were weighed at the same time. Animals were injected on days 1, 2, and 3 and allowed to recover for two more days. Injections were of 150 μg purified mouse AMF/PGI or BSA (Sigma) in 100 μl of sterile PBS. The curves are not statistically significant (p > 0.05) between the two groups by 2-way ANOVA, with n = 10 mice/group.
Figure 2. Protocol was similar to that described under Figure 1, except that the injections were of 500 μg aliquots of the proteins, in the same volume of PBS as before. There were n = 5 mice per group. The curves were analyzed for statistical significance by 2-way ANOVA, and p < 0.0001. Significance of differences between the two curves at each time point were calculated by comparing replicates of the means by row with Bonferroni’s post-test using the statistics programs in GraphPad Prizm. ** p < 0.01; *** p < 0.001. Other points n.s. (p > 0.05).

Figure 3. C2C12 mouse myoblasts (ATCC) were grown to confluence, changed to serum-free medium for 24 hrs, and then treated for 24 hrs with the indicated concentrations of recombinant mouse PGI/AMF. These cells are routinely studied for the induction of proteasomal activity (Coulombe et al, 2003; You et al, 2003), as well as being used for models of skeletal muscle cell function and differentiation (Yamaguchi, 1995). Cells were harvested, lysed by three cycles of freeze/thawing, homogenized, and centrifuged for 10 minutes at 14,000g and 4°C to sediment debris. The supernatants were adjusted to a constant protein concentration of 50 μg/ml and assayed for 20S proteasomal chymotryptic activity (Reinheckel et al, 2000) with the fluorogenic substrate, succinyl-LLVY-AMC (Calbiochem) for 1 hr at 37°C. Control values not shown, since these continue to be highly variable, and we have not yet succeeded in establishing a reproducible negative control for the assay. Differentiation of the myoblasts into myotubes, by culturing in the presence of horse serum, may resolve this problem (experiments underway).
Tumor-bone cellular interactions in skeletal metastases

J.M. Chirgwin, K.S. Mohammad, T.A. Guise
Division of Endocrinology, Department of Medicine, University of Virginia, Charlottesville, USA

Abstract

Human tumor cells inoculated into the arterial circulation of immunocompromised mice can reliably cause bone metastases, reproducing many of the clinical features seen in patients. Animal models permit the identification of tumor-produced factors, which act on bone cells, and of bone-derived factors. Local interactions stimulated by these factors drive a vicious cycle between tumor and bone that perpetuates skeletal metastases. Bone metastases can be osteolytic, osteoblastic, or mixed. Parathyroid hormone-related protein, PTHrP, is a common osteolytic factor, while vascular endothelial growth factor and interleukins 8 and 11 also contribute. Osteoblastic metastases can be caused by tumor-secreted endothelin-1, ET-1. Other potential osteoblastic factors include bone morphogenetic proteins, platelet-derived growth factor, connective tissue growth factor, stanniocalcin, N-terminal fragments of PTHrP, and adrenomedullin. Osteoblasts are the main regulators of osteoclasts, and stimulation of osteoblast proliferation can increase osteoclast formation and activity. Thus, combined expression of osteoblastic and osteolytic factors can lead to mixed metastases or to increased osteolysis. Prostate-specific antigen is a protease, which can cleave PTHrP and thus change the balance of osteolytic versus osteoblastic responses to metastatic tumor cells. Bone itself stimulates tumor by releasing insulin-like growth factors and transforming growth factor-β. Secreted factors transmit the interactions between tumor and bone. They provide novel targets for therapeutic interactions to break the vicious cycle of bone metastases. Clinically approved bisphosphonate anti-resorptive drugs reduce the release of active factors stored in bone, and PTHrP-neutralizing antibody, inhibitors of the RANK ligand pathway, and ET-1 receptor antagonist are in clinical trials. These adjuvant therapies act on bone cells, rather than the tumor cells. Recent gene array experiments identify additional factors, which may in the future prove to be clinically important targets.

Keywords: Cancer, Breast, Prostate, Bone Metastasis, Parathyroid Hormone-Related, Protein, Endothelin, Adrenomedullin, Transforming Growth Factor-β, Prostate-Specific Antigen

Introduction

The majority of patients dying from cancer of the breast or prostate have metastases to the skeleton. The affinity of these and several other solid tumors for this metastatic site is the consequence of the special microenvironment provided by bone. Stephen Paget in 1889 proposed the seed and soil hypothesis: bone provides the fertile soil in which certain cancer cell seeds prefer to grow. We now appreciate that mineralized bone matrix is a rich storehouse of growth factors', which are mobilized by osteoclastic bone resorption.

The authors have no conflict of interest.

Corresponding author. John M. Chirgwin, Ph.D. Division of Endocrinology, PO Box 801421, Department of Medicine, University of Virginia, Charlottesville, VA 22908, USA
E-mail: jc3qb@virginia.edu

Accepted 11 February 2004

The released growth factors enrich the local microenvironment. A main effect of the factors appears to be alteration of the tumor cell phenotype rather than an increased growth rate. Tumor cells in turn secrete additional factors that act upon bone cells, causing the responses that characterize the osteolytic and osteoblastic metastases. Local interactions between tumor cells and bone form a vicious cycle, which underlies the development of skeletal metastases. Interactions between tumor cells and bone cells change the phenotypes of both.

The basic mechanisms of cancer metastases to specific sites have been controversial. Cancer cells in vivo continue to mutate. The ability of cancer cells to metastasize is characteristic of advanced disease and could occur only after the gradual accumulation of a necessary set of pro-metastatic mutations. However, recent experiments suggest that a constellation of expressed genes necessary for metastasis to bone pre-exists within the primary breast tumor. Thus, bone-specific metastases are the consequence of a selection
of variants from a heterogeneous population of cells within the primary tumor, plus changes in gene expression induced by bone factors. Cells of the osteoblastic lineage appear to be the main targets of tumor-secreted factors. Bone-derived transforming growth factor-β (TGFβ) is a major factor regulator of tumor cell behavior in bone.

There are no convenient animal models where primary tumors reproducibly metastasize to bone. Many of the results described here use an animal model in which human tumor cells are inoculated into immuno-deficient mice. Injection into the venous circulation most often results in tumor cell entrapment within the capillary beds of the lung or liver. However, careful tumor administration directly into the left cardiac ventricle can result in 100% incidence of bone metastases with many tumor cell lines (Table 1). Osteolytic lesions are detected by X-ray as early as 3 weeks and can be quantified by image analysis. Osteoblastic lesions may take up to 6 months to develop in nude mice, and the lesions cannot be quantified radiographically.

Osteolytic metastases

Destructive bone lesions are characteristic of breast cancer. The most prominent cause of bone destruction is parathyroid hormone-related protein, PTHrP, which is secreted by many cancer types and, when systemically elevated, is responsible for humoral hypercalcemia of malignancy (HHM). Breast and lung cancer cells that secrete PTHrP in concentrations insufficient to induce HHM still cause extensive osteolytic bone destruction in nude mice. Bone lesions and tumor burden can be significantly decreased, and survival increased, by treatment with PTHrP-neutralizing antibody. The antibody has been humanized and is in clinical trials against HHM.

PTHrP was originally suspected to play a role in osteolytic metastases based on its known role as a stimulator of hypercalcemia, plus its high expression by tumor cells in bone versus soft tissue sites in patients. These results suggested that PTHrP expression by the primary tumor might be prognostic of metastases to bone. This is not the case. In a prospective study, PTHrP expression by the primary tumor was an independent prognostic marker of improved survival and decreased metastasis to bone. PTHrP is a complex, multifunctional protein and appears to play independent roles in primary and metastatic cells. It is likely that the expression of PTHrP by breast cancer cells in bone is the result of induction of its gene by factors in bone, such as TGFβ.

PTHrP cannot be the only factor responsible for bone metastases, and a number of other factors play either a contributory or PTHrP-independent role. Candidate factors that may contribute to PTHrP-induced osteolytic lesions are interleukin (IL)-11, macrophage colony-stimulating factor (M-CSF), and vascular endothelial growth factor (VEGF). PTHrP-independent factors have also been reported, including IL-8, which can directly stimulate the osteoclast.

Kang et al. compared less- and more-metastatic variants of a breast cancer cell line by gene expression profiling. They identified mRNAs whose expression strongly correlated with increased bone metastasis. Five of the mRNAs encoded IL-11, matrix metalloproteinase (MMP)-1 osteopontin, connective tissue growth factor (CTGF), and CXCR-4. MMP-1 is an interstitial collagenase made by osteoblasts. It cleaves collagen at a site resistant to osteoclastic enzyme hydrolysis and may be rate-limiting in normal bone resorption. Osteopontin plays a complex role in metastasis, including modulation of anti-tumor immune responses and is differentially regulated in tumor cells metastatic to bone versus other sites. CTGF is a potent osteblast-stimulatory factor, as well as being expressed by tumor cells. CXCR-4 is the receptor for the chemokine SDF-1 and functions in the attraction of breast cancer cells to specific metastatic sites including, but not limited to, bone. Kang et al. found that the pro-metastatic gene set was coordinately increased in cells that pre-existed in the original cell population. The authors attempted to convert low-metastatic MDA-MB-231 breast cancer cell line clones into ones highly metastatic to bone by overexpressing each of the five individual factors. They found that conversion of the cells to a phenotype of aggressive metastasis to bone required co-transduction of combinations of four of the five factors. The results strongly support a multi-factorial mechanism underlying organ-specific metastases.

Many osteolytic factors act via osteoblasts and stimulate osteoclastic bone resorption indirectly, rather than acting directly on cells of the osteoclast lineage. This has been shown for PTHrP, which induces osteoblastic expression of RANK ligand. IL-11 can act similarly, while M-CSF and VEGF serve as co-factors for the RANK ligand-stimulated differentiation of hemopoietic precursors into active osteoclasts.

Osteoblastic metastases

Metastases with net formation of disorganized new bone are characteristic of prostate cancer and also occur in 15% of breast cancer bone metastases. The tumor-induced lesions are characterized by formation of new but abnormal and disorganized new bone, and they are accompanied by increased bone resorption. A number of candidate factors made by tumor cells could stimulate osteoblasts, but progress has lagged in the area until recently. Endothelin-1 (ET-1), a 21-amino acid vasoactive peptide, is a potent stimulator of new bone formation. It is secreted by tumor cells and can cause osteoblastic metastases in the nude mouse model. Metastases are effectively blocked with a selective antagonist of the endothelin A receptor. This orally active antagonist is in clinical trials in men with advanced metastatic prostate cancer. The vicious cycle model predicts that osteoblasts, osteoclasts and tumor cells cooperate to cause the pathology of bone metastases. The endothelin receptor antagonist blocks the activation of osteoblasts by tumor-produced ET-1. It also decreases osteoclastic bone resorption, as indicated by decreases in markers of resor-
<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Bone Metastases</th>
<th>PTHrP</th>
<th>IL-6</th>
<th>IL-11</th>
<th>VEGF</th>
<th>Other Osteolytic Factors</th>
<th>ET-1</th>
<th>AM</th>
<th>Other Blastic Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZR-75-1</td>
<td>OB</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>99±1.5</td>
<td>81±5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCF-7</td>
<td>OB</td>
<td>0</td>
<td>3.3±0.2</td>
<td>0</td>
<td>180±2</td>
<td>19±2</td>
<td>+A</td>
<td></td>
<td>PDGFB</td>
</tr>
<tr>
<td>[171±20]M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T47D</td>
<td>OB</td>
<td>0</td>
<td></td>
<td>0</td>
<td>[68±12]M</td>
<td>227±12</td>
<td>+A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BT483</td>
<td>M</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td>22±6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA-</td>
<td>OL</td>
<td>0.54±0.1</td>
<td>360</td>
<td>240±3</td>
<td>1258±34</td>
<td>IL-8C</td>
<td>0</td>
<td>+</td>
<td>CTGF</td>
</tr>
<tr>
<td>MB-231</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BT549</td>
<td>OL</td>
<td>0.44±0.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA-</td>
<td>OL</td>
<td>0.29±0.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MB-435s</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HS578T</td>
<td>N</td>
<td>0.46±0.05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA-</td>
<td>N</td>
<td>0.4±0.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MB-436</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA-</td>
<td>N</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MB-361</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prostate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DU-145</td>
<td>N</td>
<td>0.75±0.08</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNCAPl</td>
<td>N</td>
<td>0.08±0.08</td>
<td></td>
<td></td>
<td></td>
<td>470L</td>
<td></td>
<td></td>
<td>[4±0.3]L</td>
</tr>
<tr>
<td>PC-3</td>
<td>OL</td>
<td>12±0.8</td>
<td>&lt;25L</td>
<td>&lt;25L</td>
<td></td>
<td></td>
<td>0</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>[1.2±0.2]L</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RWGT2F</td>
<td>OL</td>
<td>64±2</td>
<td>117±2</td>
<td>0</td>
<td>1233±14</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBC-5G</td>
<td>OL</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A549</td>
<td>OL</td>
<td>+M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HARAI</td>
<td>OL</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ovary</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHO-K1</td>
<td>OL</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Cancer Cell Lines and Phenotypes of Bone Metastases. PTHrP in pM/10⁵ cells/48 hr by Nichols Institute 2-site IRMA. ET-1, IL-6, IL-11, VEGF in pg/ml/10⁵ cells/48 hr by R&D Systems immunoassays. OB = osteoblastic, OL = osteolytic, M = mixed, N = none, when cells are inoculated into the arterial circulation of nude mice via the left cardiac ventricle. Most data from Yin et al. Most data from Yin et al. AM = adrenomedullin (Miller et al.). PDGFB = platelet-derived growth factor B chain (Yi et al.). IL-8 = interleukin-8 (Bendre et al.). CTGF = connective tissue growth factor (Kang et al.). AM = adrenomedullin (Abasolo et al.). (Gallwitz et al.). (Miki et al.). (Hastings et al.). (Iguchi et al.). (Chiao et al.). FMol/mg protein (Rocchi et al.). pg/mg protein (Dall’Era et al.). Arbitrary mRNA units (Scott et al.). Remaining data, indicated by pluses, are unpublished from the authors’ laboratory. Note that some of these cells (MCF-7 and MDA-MB-231, for examples, vary in PTHrP production depending on source of the cell line). A number of cell lines, scored N here, cause bone responses when injected directly into the marrow cavity of the tibia or femur. Most of the cell lines are of human origin.
tion seen in the patient trials. Conversely, bisphosphonates effectively reduce skeletal-related events in prostate cancer. These observations support an important role for the vicious cycle in patients.

Other factors responsible for osteoblastic metastases remain to be identified. Such factors need to meet two initial criteria: 1) ability to stimulate osteoblastic new bone formation, and 2) expression by cancer cells. The bone morphogenetic proteins (BMPs) are obvious candidates, but a causal role in bone metastases has not been demonstrated. CTGF, identified in the experiments of Kang et al. is another factor that stimulates osteoblasts. It is a normal product of hypertrophic chondrocytes and is the second of three closely related gene products CCN1-3, which are selectively expressed in certain tumor types. It is possible that CCN1 and CCN3 may contribute to bone metastases. CCN3 is expressed by prostate cancers, while CCN1, cyr61, is expressed by breast and other cancers.

Adrenomedullin (AM) is a 52-amino acid vasoactive peptide with potent bone-stimulatory actions in vitro and in vivo. It is made by many cancers, including breast and prostate. We have recent data that it increases bone metastases in vivo. We tested the A549 human lung adenocarcinoma cell for its ability to form bone metastases when inoculated into the left cardiac ventricle. Animals developed osteolytic metastases after five weeks. These cells express PTHrP, ET-1, and AM. AM secretion was reduced 50% by stable expression of AM siRNA. These cells, made by Dr. Alfredo Martinez at the National Cancer Institute, caused fewer metastases and increased survival, compared to empty vector-transfected A549 cells (unpublished results). In experiments the human prostate cancer cell line PC-3 was transfected with an AM expression DNA, resulting in a greater than ten-fold increase in AM secretion. These cells showed slower growth in vitro and as subcutaneous tumors; this response is opposite to that found with many other tumors, where AM is an autocrine growth stimulatory and pro-angiogenic factor. However, when these same PC-3 subclones were inoculated into nude mice, animal survival was less than half that of mice receiving control PC-3 cells. Mice with AM-overexpressing tumors showed accelerated osteolytic lesions and also adjacent areas of osteoblastic new bone formation (unpublished).

Another factor that could play a role in osteoblastic metastases is stanniocalcin, a polypeptide that is produced by cancer cells and can stimulate new bone formation.

Mixed osteolytic/osteoblastic metastases

Mixed lesions are characteristic of both breast and prostate cancers. The effect of combined expression of osteolytic and osteoblastic factors on bone has not been studied, so the net response of bone at the metastatic site is unpredictable. As noted above, osteolytic factors such as PTHrP and IL-11 act on osteoblasts to increase expression of RANK ligand. We tested the effects of introducing the osteoblastic factor, ET-1, into the PTHrP-secreting MDA-MB-231 breast cancer cell line. Instead of converting the bone response from osteolytic to osteoblastic, the bone-destructive effects were enhanced by ET-1. Some of this effect may be caused by autocrine responses of the tumor cells to ET-1. We believe that osteoblastic factors can stimulate osteoblast proliferation, increasing the population of early osteoblasts. The enlarged pool of early osteoblasts responds to osteolytic factors by increased expression of RANK ligand. A similar mechanism may be involved in the metastases caused by A549 and PC-3 cells, described in the preceding paragraph. Both cell lines secrete PTHrP and adrenomedullin, and A549s make ET-1 as well (unpublished). Thus, expression of an osteoblastic factor may not simply convert an osteolytic tumor cell into one that causes osteoblastic metastases.

Another puzzling question has been the role of PTHrP in osteoblastic metastases, especially those due to prostate cancers, which nearly always express PTHrP. A partial explanation was provided by the observation that prostate-specific antigen (PSA) is a serine protease, which cleaves PTHrP after phenylalanine residues 22 and 23. The resulting fragment fails to activate the classical PTH/PTHrP receptor. This is not the end of the story. It was later observed that the inactive fragment PTHrP1-16 increased contraction of cardiac myocytes apparently by binding to the endothelin A receptor. Binding was attributed to a 4 amino acid near-identity between the two peptides. We have extended these observations to bone. PTHrP1-23 is a potent stimulator of calvarial new bone formation at concentrations as low as 1nM (unpublished results), although this polypeptide has no detectable affinity for the type 1 PTH receptor. New bone formation was blocked by the endothelin A receptor antagonist, ABT-627. The results suggest that PSA proteolysis of PTHrP, rather than inactivating it, converts the protein from an osteolytic factor to a potent osteoblastic one. These preliminary results are in vitro and require confirmation of their physiological significance in vivo. PTHrP can also be cleaved by the neutral endopeptidases, nephrilysin, which is expressed on the surface of prostate and bone cells, so N-terminal fragments of PTHrP could play a role in normal bone metabolism.

Actions of bone on tumor cells

The effects of bone-derived factors on tumor cells remain understudied. Van der Pluijm et al. elegantly demonstrated that several mRNAs are increased in bone versus non-bone sites of human breast cancer metastases in nude mice. RNA abundances were determined by species-specific RT-PCR. PTHrP, VEGFs and M-CSF were increased specifically in bone, while several mouse markers of host angiogenesis were similarly increased. These experiments did not identify the factor(s) responsible for the bone-specific mRNA induction. Haushka et al. found that insulin-like growth factors (IGFs) -2, then -1, were the most abundant factors in bone matrix, followed by TGFβ, after which were lower concentrations of...
Figure 1. Tumor stimulation of osteoblasts can increase both new bone formation and resorption. Tumor products, such as endothelin-1 and adrenomedullin, stimulate osteoblast (ObI) proliferation. Immature osteoblasts respond to osteolytic cytokines, such as parathyroid hormone and interleukin-11, by expressing RANK ligand (Y). RANK ligand stimulates bone resorption by osteoclasts, which releases growth factors, such as transforming growth factor-β, from mineralized matrix. Mature osteoblasts synthesize growth factors, which are incorporated into bone and also enrich the local microenvironment. Growth factors stimulate tumor cells. Osteoblasts lose RANK ligand expression during maturation. The balance of osteoblast proliferation versus maturation, plus tumor production of factors like PTHrP, determines whether bone metastases are osteoblastic, osteolytic, or mixed. The new bone synthesized in osteoblastic metastases is disorganized and of poor mechanical quantity.

BMPs, fibroblast growth factors -1 and -2, and platelet-derived growth factor1 have been generically named as growth factors. However, tumor cell proliferation is generally growth factor-independent, and such proliferation is not rate-limiting for the progress of bone metastases. Experiments with inhibitors of bone responses to tumor cells (but which do not directly target the tumor cells) effectively decrease tumor burden57,58,59. These results suggest that paracrine interactions between tumor cells and bone cells are central regulators of skeletal metastases, and that the regulation is not via control of cell proliferation.

The vicious cycle

Animal models have established that bone metastases involve a vicious cycle between tumor cells and the skeleton (Figure 1). The cycle is driven by four obvious contributors: the tumor cells, bone-forming osteoblasts, bone-destroying osteoclasts, and organic bone matrix. Osteoclast formation and activity is controlled by the osteoblast, adding complexity to the vicious cycle. The mineralized matrix of bone provides a rich store of growth factors, such as insulin-like and transforming growth factors1. These factors are synthesized by osteoblasts and released by osteoclasts. The factors reach high local concentrations in the bone microenvironment and can act on tumor cells to encourage metastatic growth. The products released from resorbing bone attract tumor cells60.
In turn, breast cancers secrete many factors that act on bone cells. It is likely that at sites of osteoblastic metastases, the tumor cells continue to secrete osteolytic factors, such as parathyroid hormone-related protein, which stimulate bone resorption. Therapies targeting the vicious cycle can decrease metastases by lowering the concentrations of growth factors in bone. It is characteristic of skeletal metastases that the properties of the bone are altered, contributing to the clinical pathology seen in patients. As disease progresses, the bone and the bone cells probably become more and more abnormal, under the continuing influence of tumor-secreted factors. It should be borne in mind that the images of metastases seen in animal models represent a much-simplified version of pyrophosphate by a carbon in the bisphosphonate backbone. It is likely that at sites of osteoblastic metastases, the tumor cells continue to secrete osteolytic factors, such as parathyroid hormone-related protein, which stimulate bone resorption. Therapies targeting the vicious cycle can decrease metastases by lowering the concentrations of growth factors in bone. It is characteristic of skeletal metastases that the properties of the bone are altered, contributing to the clinical pathology seen in patients. As disease progresses, the bone and the bone cells probably become more and more abnormal, under the continuing influence of tumor-secreted factors. It should be borne in mind that the images of metastases seen in animal models represent a much-simplified version of pyrophosphate by a carbon in the bisphosphonate backbone.

Roles of other cells in bone to skeletal metastases

It is an oversimplification to consider only osteoblasts and osteoclasts as the interacting partners of tumor cells in the vicious cycle of cancer bone metastases. Vascular endothelial cells are a major fourth cellular component. Most of the tumor-produced factors discussed above are vasoactive and many are pro-angiogenic, including endothelin, adrenomedullin, IL-8, the CCN proteins, stanniocalcin, as well as VEGF. PTTHp may be anti-angiogenic. These same angiogenic factors are also increased by the hypoxic response in tumor cells, including endothelin, adrenomedullin, the CCN proteins, and stanniocalcin. To further complicate the situation, many of these factors are both regulated by and regulators of VEGF, and many are also TGFβ-regulated genes. Thus, there must be an extremely complex cross-talk between endothelial cells, bone cells, and tumor cells at the metastatic site. Making sense of these interactions will require the development of novel and subtle experimental strategies.

Endothelial cells in bone differ from the cells lining blood vessels in other organs, which could contribute to the bone tropism of certain tumors. Just as tumor-secreted factors can alter the phenotypes of bone cells in the vicinity of metastases, such factors will probably also alter the behavior of endothelial cells. Van der Pluijm et al. observed specific changes in host vascular markers in bone versus non-bone metastatic sites. Di Raimondo et al. similarly detected angiogenic factors at higher concentrations in bone marrow plasma than in the peripheral circulation of patients with multiple myeloma, suggesting the specific induction of angiogenic factor expression within the bone microenvironment of patients with cancer in the skeleton. Tumor cells are also likely to perturb the lineages of cells in bone. Bone marrow is a major site of stem cells, including the stem cells of the bone stromal lineage, and cells in bone such as pericytes could alter their differentiation under the influence of tumor-produced factors. Thus, tumor cells could alter the supply of osteoblastic precursors and also alter the differentiation of hematopoietic precursors into osteoclasts. The animal model that is the focus of this article relies on T-cell deficient nude mice, which ignores the contribution in patients of the immune system to both normal bone cell function, as well as to cell-mediated immune surveillance and killing of tumor cells.

Clinical applications

The bisphosphonates are a class of drugs that resemble pyrophosphate. The replacement of the central oxygen of pyrophosphate by a carbon in the bisphosphonate backbone results in resistance to hydrolysis and confers high affinity for bone mineral, which is the basis for bisphosphonate-radiouclide conjugates as diagnostic bone-scanning agents. The bisphosphonates have high affinity for bone, where they can persist for years. They are released at high concentrations in areas of active bone remodeling and are absorbed by nearby cells. They inhibit cells by several mechanisms, including the stimulation of apoptosis. Bisphosphonates are effective in animal models and the clinic. Whether bisphosphonates have significant effects in vivo on tumor cells or angiogenesis, especially at non-bone sites where their concentrations are low, is controversial.

An inhibitor of intracellular src signaling, when modified by the addition of a pair of phosphate groups, inhibited osteoclastic bone resorption. This approach could add bone specificity to existing chemotherapeutic and adjuvant compounds. Recombinant osteoprotegerin decreased osteolytic destruction and tumor burden in bone, without affecting metastases to soft-tissue sites in an animal model, and decreased cancer bone pain. Recombinant osteoprotegerin entered clinical trials but is likely to be superceded by neutralizing antibodies against RANK ligand. A recent study identified 6-thioguanine and 6-thioguanosine as effective inhibitors of PTTHp transcription. These agents have long been used against leukaemias and several inflammatory disorders. They were effective in animal models of humoral hypercalcemia of malignancy and breast cancer bone metastases. Endothelin receptor antagonists are in extensive clinical trials, and their efficacy against osteoblastic metastasis is discussed above. Most of these adjuvant treatments target bone cells, but it may be possible to block the effects on tumors of bone-derived factors such as TGFβ.

Treatment options

Bisphosphonate drugs are currently approved for skeletal metastases due to multiple myeloma and solid tumors of the breast and prostate. In the last case, an anti-resorptive is effective against what are predominantly osteoblastic metastases. In fact, osteoblastic metastases are accompanied by active bone remodeling, and prostate cancer patients with bone metastases have markers of bone resorption higher than those seen in patients with osteolytic disease.
Bisphosphonates are also effective in animal models of osteoblastic bone metastases. The results are consistent with the importance of the vicious cycle, outlined above and in Figure 1, to both osteolytic and osteoblastic diseases. The role of a vicious cycle in osteoblastic metastases is also supported by the observation that when patients with advanced metastatic prostate cancer were treated with the endothelin A receptor antagonist ABT-627, atresiantan, markers of bone resorption were decreased. Trials are now underway to test whether combining a bisphosphonate drug with an endothelin receptor antagonist is more effective than the single agent treatments.

Future directions and limitations

Areas of active research include the continuing identification of candidate osteolytic and osteoblastic factors. Many of those already identified require substantial further testing in vivo to determine whether they are valid targets for therapeutic intervention. They include IL-8, IL-11, CTGF, adrenomedullin, stanniocalcin, and CXCR-4. Angiogenesis is of obvious central importance in bone metastases. Many of the factors made by tumor cells are increased by hypoxia and in turn are angiogenic, in addition to having stimulatory actions on bone cells.

The roles of the abundant, bone-derived insulin-like growth factors need to be tested for their contributions to metastases to bone. IGF-2 is the most abundant bioactive factor in the mineralized matrix, but its role in skeletal metastasis, along with those of IGF-1, has been little studied. The effects of these molecules, through activation of the type 1 IGF-1 receptor on tumor cells and bone cells, are likely to be complex and extend beyond stimulation of growth. Actions of secreted IGFs are controlled by the IGF binding proteins. The extremely complex relationship between bone metastases and angiogenesis, discussed above, remains to be clarified.

The animal models, which are the focus of this article, have been limited to a modest number of cultured cell lines (Table 1). This is a strength in terms of defining molecular mechanisms, but it is clearly a weakness for understanding the more diverse and complex situations encountered in the clinic. We believe that this weakness is not effectively addressed by repeating the animal model experiments with more cell lines, even if funding were available for such confirmatory studies. A goal of the animal models is to provide platforms for pre-clinical testing of therapeutic interventions. If the animal models provide useful guidance in improving the care of patients with skeletal metastases, then they will have served their purpose well.

On a broader scale, are the clinical consequences of bone metastases, in particular severe bone pain and systemic weight loss (cachexia). ET-1, for example, is nociceptive. Mechanisms of bone pain are specific and under active investigation. It seems likely that bone metastases release unknown factors into the circulation, which stimulate wasting of skeletal muscle. These syndromes are of great consequence to the patients who suffer from cancers of the breast and prostate, which are incurable once they become housed in bone. It is now appreciated that the standard treatments for patients with cancers of the breast and prostate result in bone loss. Not only does this result in skeletal morbidity for the patients, but increased bone turnover could enhance metastases to bone by stimulating the vicious cycle. Patients with treatment-related bone loss should benefit from therapy with bisphosphonate anti-resorptive drugs. Tumor-bone interactions, and the secreted factors which mediate them, offer targets for future therapeutic intervention to ameliorate or perhaps prevent skeletal metastases.

Acknowledgments

Work in the authors' laboratory was supported by funding from the Gerald D. Aurbach Endowment and the Mellon Institute of the University of Virginia Cancer Center, and research grants from the NIH (R01 CA69158) and the U.S. Army (DAMD17-99-1-9401) to TAG and the Veterans Administration Research Service (Merit Award) and the U.S. Army (DAMD17-98-1-8245 and DAMD17-02-1-0586) to JMC. Mr. Cliff Martin assisted in the preparation of the figure.

References

8. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteoly-


16. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolyis of metastatic bone disease. Bone 2003; 33:28-37.


25. Nelson JB, Hedican SP, George DJ, Reddi AH, Furthermore, it is identified that the pathogenesis of metastatic bone metastases: increased incidence in bone compared with other sites. Cancer Res 1991; 51:3059-3061.


35. Tsai MS, Bogart DF, Li P, Mehmi I, Lupu R.


The Crystal Structure of Mouse Phosphoglucose Isomerase at 1.6 Å Resolution and its Complex with Glucose 6-Phosphate Reveals the Catalytic Mechanism of Sugar Ring Opening

J.T. Graham Solomons¹, Ella M. Zimmerly¹, Suzanne Burns²
N. Krishnamurthy¹, Michael K. Swan¹, Sandra Krings¹, Hilary Muirhead³
John Chirgwin⁴ and Christopher Davies⁵*

¹Department of Biochemistry and Molecular Biology, Medical University of South Carolina Charleston, SC 29425, USA
²Research Service, Veterans Administration Medical Center San Antonio, TX 78230, USA
³School of Medical Sciences University of Bristol, Bristol BS8 1TD, UK
⁴Department of Medicine University of Virginia Charlottesville, VA 22908 USA

Phosphoglucose isomerase (PGI) is an enzyme of glycolysis that interconverts glucose 6-phosphate (G6P) and fructose 6-phosphate (F6P) but, outside the cell, is a multifunctional cytokine. High-resolution crystal structures of the enzyme from mouse have been determined in native form and in complex with the inhibitor erythrose 4-phosphate, and with the substrate glucose 6-phosphate. In the substrate-bound structure, the glucose sugar is observed in both straight-chain and ring forms. This structure supports a specific role for Lys518 in enzyme-catalyzed ring opening and we present a “push–pull” mechanism in which His388 breaks the O5–C1 bond by donating a proton to the ring oxygen atom and, simultaneously, Lys518 abstracts a proton from the C1 hydroxyl group. The reverse occurs in ring closure. The transition from ring form to straight-chain substrate is achieved through rotation of the C3–C4 bond, which brings the C1–C2 region into close proximity to Glu357, the base catalyst for the isomerization step. The structure with G6P also explains the specificity of PGI for glucose 6-phosphate over mannose 6-isomerase (M6P). To isomerize M6P to F6P requires a rotation of its C2–C3 bond but in PGI this is sterically blocked by Gln511.

© 2004 Elsevier Ltd. All rights reserved.

Keywords: phosphoglucoisomerase; aldose-ketose isomerase; enzyme mechanism; cytokine; X-ray crystallography

Introduction

Phosphoglucoisomerase (PGI; EC 5.3.1.9) catalyses the interconversion of glucose 6-phosphate (G6P) and fructose 6-phosphate (F6P), a reaction with direct roles in glycolysis and gluconeogenesis and, indirectly, other branches of carbohydrate metabolism such as the pentose phosphate pathway. In addition to its enzymatic activity, PGI acts as a cytokine in a wide variety of extracellular activities,¹–³ and hence the enzyme now carries many names, including that of autocrine motility factor (AMF) and maturation factor (MF), but how the protein functions in this context is unclear. PGI is better characterised as an enzyme, but some key aspects of its catalytic mechanism remain unresolved, and these are addressed here.

PGI belongs to the aldose-ketose isomerase family of enzymes, all of which transfer a hydrogen atom between C1 and C2 of their respective substrates. This hydrogen atom can move by one of two mechanisms: as a proton via a cis-enediol/cis-enediolate intermediate or more directly as a hydride.⁴ The existence of the cis-enediol mechanism...
is well established for PGI, but for many years, the identity of the enzymatic base responsible for proton abstraction from C2 of G6P or C1 of F6P was unknown. Recent determination of the crystal structures of PGI from mammalian sources, however, have led to proposals that Glu357 is responsible.

In contrast to other aldose-ketose isomerases, such as triose phosphate isomerase, PGI uses a sugar substrate that exists in solution overwhelmingly in the hemiacetal or hemiketal ring form, and indeed, a crystal structure of rabbit PGI in complex with F6P shows the substrate bound in the ring form. But for proton transfer to occur between C1 and C2, the substrate must be in the open-chain form and, hence, the enzyme catalyzes a second activity, that of ring opening. In agreement with this, crystal structures of inhibitor-bound PGIs show the ligand to be in the open-chain conformation. The nearest residues to the sugar ring oxygen atom are His388 and Lys518 (mammalian numbering), and, of these, histidine is most likely to act as an acid catalyst in ring opening but how the lysine residue contributes to this process, if at all, is unknown.

Another unresolved issue in the catalytic functioning of PGI is how the enzyme permits rotation of the substrate within the active site without compromising specificity. Such a rotation must occur after the ring-opening step in order to bring the C1-C2 region of the substrate in close proximity to Glu357 for isomerisation. A similar rotation might occur during the anomerisation of its substrates (a third enzyme activity for PGI). In principle, such rotations when coupled with isomerization could generate mannose 6-phosphate. However, PGI is essentially specific for F6P and G6P, and it will not isomerise mannose 6-phosphate to F6P except at an extremely slow and non-physiological rate. Interestingly, distantly related members of the PGI superfamily from certain Archaea do show dual phosphoglucone/ phosphomannose isomerase (PGI/PMI) activities but how "conventional" PGI prevents the epimerisation of G6P to M6P is unknown.

Here, we present a series of high-resolution crystal structures of PGI derived from mouse. These include complexes with the inhibitor erythroside 4-phosphate and with the substrate, glucose 6-phosphate. The complex with G6P provides unique insight because in this structure the substrate is present in both the open-chain form and the ring form. Together, these data permit a definitive and comprehensive description of the catalytic mechanism of this interesting multifunctional enzyme.

Results

Structure determination

Phosphoglucone isomerase from mouse crystallized relatively easily over wells containing 1.6-2.1 M ammonium sulphate buffered in the pH range 6.5-9.5. The native crystal used in this study was harvested from 1.9 M ammonium sulphate, 100 mM Tris-HCl (pH 8.5). The crystals grow as large plates of approximate dimensions 1 mm × 1 mm × 0.2 mm and were typically cut into smaller pieces for data collection. Initial diffraction analysis revealed that the crystals belong to space group P2₁ or P2₁₁ with cell dimensions a = 69.2 Å, b = 116.1 Å, c = 73.1 Å and β = 101.3°. An estimate of the solvent content (46.2%, v/v) indicated that the asymmetric unit of these crystals is a dimer of PGI, which corresponds to the biological form of this enzyme. A complete dataset extending to 1.6 Å resolution was collected (Table 1) and examination of the systematic absences revealed the space group to be P2₁. The structure was solved by molecular replacement and refined to a crystallographic R-factor of 21.2% (Rfree 24.5%) with excellent stereochemistry. The final model comprises two PGI subunits (residues 1-556), 1017 water molecules as well as molecules of sulphate, β-mercaptoethanol (BME) and glycerol, derived from the crystallization solution. For both subunits, only the methionine at the N terminus and the C-terminal residue are not visible in the electron density map.

Structure description

As expected, the fold of mouse PGI is essentially the same as PGIs from other mammalian sources and, hence, will be described only briefly. Each subunit comprises two domains of nearly equal size, but historically these have been termed small and large. The small domain is built around a five-stranded parallel β-sheet, whereas the large domain contains a mixed six-stranded parallel/antiparallel β-sheet. Both sheets are packed on both sides by α helices. Two interesting features of this fold are a "hook" comprising residues 440-465 and a 45 residue extension at the C terminus, both of which make extensive interactions with the partner subunit in the dimer. The active site comprises highly conserved residues, including Glu357, His388 and Lys518, all of which have a role in catalysis. The histidine residue belongs to the partner subunit of the dimer and thus the active site is comprised of protein chains from both subunits.

The two subunits in the dimer superimpose closely with an rms deviation between all main-chain atoms of 0.93 Å. The only structural differences of significance map to the active-site regions, which correlate with the binding of species from the crystallization solution, and there is a slight shift in the relative position of the hook structure. In molecule A, the active site contains one sulphate ion, which occupies the same position as the phosphate group of the substrate molecules for PGI. There is some electron density located between threonine residues 211 and 214 and Lys518, which might be a molecule of BME. The view in the active site of molecule B is different: two sulphate ions
Mechanism of Sugar Ring Opening

Table 1. X-ray diffraction data and refinement statistics

<table>
<thead>
<tr>
<th>A. Data collection</th>
<th>Native</th>
<th>E4P</th>
<th>G6P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concentration of soak (mM)</td>
<td>-</td>
<td>5</td>
<td>45</td>
</tr>
<tr>
<td>Time of soak (minutes)</td>
<td>90</td>
<td>45</td>
<td>90</td>
</tr>
<tr>
<td>Resolution range (Å)</td>
<td>50-1.6 (1.66-1.60)</td>
<td>54-1.7 (1.76-1.70)</td>
<td>45-1.6 (1.66-1.6)</td>
</tr>
<tr>
<td>Rmerge (%)</td>
<td>7.5 (42.2)</td>
<td>6.7 (27.1)</td>
<td>5.7 (36.9)</td>
</tr>
<tr>
<td>Redundancy</td>
<td>7.3 (5.9)</td>
<td>4.2 (3.0)</td>
<td>6.0 (2.8)</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>99.5 (96.4)</td>
<td>97.5 (81.8)</td>
<td>94.7 (79.9)</td>
</tr>
<tr>
<td>B. Refinement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resolution range (Å)</td>
<td>15.0-1.6</td>
<td>50.0-1.7</td>
<td>45-1.6</td>
</tr>
<tr>
<td>Sigma cut-off applied</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>No. total reflections used</td>
<td>146,126</td>
<td>118,864</td>
<td>143,578</td>
</tr>
<tr>
<td>No. β-mercaptoethanol molecules</td>
<td>5</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>No. glycerol molecules</td>
<td>10</td>
<td>7</td>
<td>12</td>
</tr>
<tr>
<td>No. sulphate molecules</td>
<td>1017</td>
<td>832</td>
<td>838</td>
</tr>
<tr>
<td>No. water molecules</td>
<td>21.3</td>
<td>19.2</td>
<td>17.9</td>
</tr>
<tr>
<td>R-factor (%)</td>
<td>21.1</td>
<td>19.0</td>
<td>17.8</td>
</tr>
<tr>
<td>Rfree (%)</td>
<td>21.3</td>
<td>19.2</td>
<td>17.9</td>
</tr>
<tr>
<td>rms deviations from ideal stereochemistry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bond lengths (Å)</td>
<td>0.010</td>
<td>0.008</td>
<td>0.011</td>
</tr>
<tr>
<td>Bond angles (°)</td>
<td>1.16</td>
<td>1.05</td>
<td>1.21</td>
</tr>
<tr>
<td>Overall B-factor (Å²)</td>
<td>24.4</td>
<td>19.1</td>
<td>23.8</td>
</tr>
<tr>
<td>Mean B-factor (main-chain) (Å²)</td>
<td>22.4</td>
<td>17.7</td>
<td>21.2</td>
</tr>
<tr>
<td>Mean B-factor (side-chains and water molecules) (Å²)</td>
<td>0.42</td>
<td>0.31</td>
<td>0.45</td>
</tr>
<tr>
<td>RMS deviation in main-chain B factor (Å')</td>
<td>26.1</td>
<td>20.3</td>
<td>25.6</td>
</tr>
<tr>
<td>RMS deviation in side-chain B factors (Å')</td>
<td>1.31</td>
<td>1.01</td>
<td>1.39</td>
</tr>
<tr>
<td>Ramachandran plot</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Residues in most-favoured region (%)</td>
<td>89.4</td>
<td>90.0</td>
<td>89.1</td>
</tr>
<tr>
<td>Residues in additionally allowed regions (%)</td>
<td>10.6</td>
<td>9.8</td>
<td>10.9</td>
</tr>
<tr>
<td>Residues in generously allowed regions (%)</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
<tr>
<td>Residues in disallowed regions (%)</td>
<td>0.0</td>
<td>0.1</td>
<td>0.0</td>
</tr>
</tbody>
</table>

Rmerge = Σ| Ii − Im | / ΣIi, where Ii is the intensity of the ith measured reflection and Im is the mean intensity of all symmetry-related reflections. Figures within parentheses are for the outer-resolution shell.

have bound and neither overlaps with the phosphate-binding site. One is in approximately the same position as the βME-like density in monomer A, whereas the other occupies a unique position adjacent to Gly158, Gln353 and Glu357, which corresponds approximately with the site of hydrogen transfer during the isomerase reaction.

When comparing previous structures of PGI from mammalian sources, we have noted a conformational change within the small domain of the protein induced by the binding of substrate, and in the case of human PGI, by sulphate alone. In both cases, either the phosphate group of the sugar substrate or a sulphate ion occupying that position induces a closure of some elements of the small domain around the phosphate-binding site.

Interestingly, in the structure of mouse PGI, both open and closed forms are present (Figure 1). In molecule A, the sulphate ion occupies the phosphate-binding site and the conformation is closed, whereas in molecule B, although two molecules of sulphate have bound, none overlaps with the phosphate-binding site and hence the conformation is open.

Complex with erythrose 4-phosphate

Erythrose 4-phosphate (E4P) is a well-known inhibitor of PGI with a Ki of 0.7 μM against the enzyme isolated from rabbit muscle. The structure of mouse PGI in complex with E4P was determined to 1.7 Å resolution (Table 1). This structure refined with a better agreement between the model and data than the native structure and has an R-factor of 19.1% (Rfree 21.5%). Density corresponding to bound E4P was clear at both active sites (Figure 2). Since the phosphate-binding site of molecule B is now occupied by a phosphate group, the conformation of the small domain has now switched to a closed conformation when compared to the native enzyme. Hence, the contacts made by E4P are essentially the same in both active sites of the dimer. As expected, other known conformational changes in response to ligand binding have occurred. These are of the 310 helix comprising residues 383-389, and a section of helix α23 comprising residues 512-522. Both of these bring highly conserved amino acids, His338 and Lys518, respectively, toward the active site when compared with the sulphate-bound "native" structure. The same structural changes have been observed in other mammalian PGI.

Numerous enzyme–ligand contacts contribute to the binding of E4P (Figure 2). The side-chains of Ser159, Ser209, Thr211, Thr214 and the backbone amide groups of Lys210 and Thr211, as well as several water molecules, orient the phosphate group. Lys518 contacts both O3 and O4 of the inhibitor, and O3 is contacted by His388. O2 contacts the amide group of Gly158 and a water molecule. The positions of oxygen atoms O2, O3
Mechanism of Sugar Ring Opening

Glu357 and Gln353, and the main-chain amide group of Gly158. O1(B) also contacts Glu357 and makes a water-mediated contact with Arg272. Although not charged, this inhibitor mimics spatially a carboxylate group, and therefore its mode of inhibition may actually be very similar to other inhibitors of PGI, such as 6-phosphogluconate (6PG) and 5-phosphoarabinonate (PAB), which are carboxylic acids and not aldoses.

Complex with glucose 6-phosphate

Crystals of mouse PGI were soaked in 5 mM fructose 6-phosphate for 45 minutes, and a dataset extending to 1.6 A was collected on a synchrotron source. After a single round of refinement, density corresponding to a bound substrate was observed in the active site of molecule A. Initially, an attempt was made to model this density as fructose 6-phosphate, but it soon became apparent that the ring-shaped density could accommodate only a six-membered sugar ring, rather than five, and hence glucose 6-phosphate was modeled instead. The tight fit of the G6P ring within the density suggests that the ring bond (O5-C1) may be broken, but this level of detail cannot be resolved unambiguously at the current resolution of the data. Irrespective, it is clear that, in this crystalline form of the PGI dimer, one of the active sites is catalytically competent and has converted F6P to G6P. After further rounds of refinement, persistent $|F_o| - |F_c|$ density remained that was contiguous with that of the substrate. The only interpretation for this density was that a proportion of glucose 6-phosphate was present in the open-chain form. Hence, the final structure contains glucose 6-phosphate in both ring and open-chain forms, each assigned an occupancy of 70% and 30%, respectively. The atoms of each form of the sugar refined to reasonable $B$ values, comparable with the overall $B$ value of the structure, and both the positive and the negative contours of the $|F_o| - |F_c|$ difference density contain only minor peaks, supporting the interpretation of the electron density. Unbiased electron density within the active site, corresponding to these two forms of G6P, is shown in Figure 3(a). At the current resolution, the electron density cannot distinguish a distinct conformer for the sugar ring of G6P and suggests a mixed population of boat and chair forms.

Unlike the structure in complex with E4P, the view of the two active sites in the mPGI-G6P complex structure is different because G6P has bound only to the active site of molecule A. The active site of molecule B appears to be occupied instead by two molecules of sulphate: the stronger of these, as evidenced by the electron density and the refined $B$ values, is in the same position as the substrate phosphate-binding site and the other weaker site lies close to Gly158 and Glu357. Thus, in molecule B, the pattern of phosphate binding has changed somewhat between the G6P-soaked and sulphate-bound "native" structures. The same

Figure 1. Conformational differences between the two subunits of mouse PGI caused by binding of sulphate ions from the crystallization solution. This superimposition of the protein backbones of the enzyme shows a section of the small domain near the active site that exists in both "open" and "closed" forms. The backbone of molecule A is coloured blue and that of molecule B is grey. The sulphate ions are shown in ball-and-stick format in which the bonds are the same colour as their respective subunits. The elements of secondary structure are labeled according to human PGI. This Figure was prepared using MOLSCRIPT and Raster3D.

and O4 overlap very closely with those of water molecules in the native structure. The most interesting aspect of the binding, however, is the apparent dual position of O1. During refinement of the crystal structure, a peak of density in the $|F_o| - |F_c|$ electron density map adjacent to C1 indicated that the O1 atom occupied two alternative conformations, termed O1(A) and O1(B). This was observed in both subunits of the enzyme. A series of refinements showed that the magnitude of the $|F_o| - |F_c|$ peaks were reduced most when these positions were each assigned an occupancy of 50% (in both subunits). O1(A) contacts the side-chains of
Mechanism of Sugar Ring Opening

Figure 2. The structure of mouse PGI in complex with erythrose 4-phosphate (E4P) at 1.7 Å resolution. A stereo picture of the active site region, showing unbiased |Fo|−|Fc| electron density of the bound inhibitor, contoured at 1 σ and coloured blue. The active-site residues and E4P are shown in bond form. Water molecules are represented as red spheres and potential hydrogen bonds are shown as broken lines. This shows the active site of molecule A but the view in molecule B is the same. The hash (#) denotes that a residue comes from the adjacent subunit. This Figure was prepared using Pymol (http://pymol.sourceforge.net/).

sulphate molecule near Gly158 and Glu357 is seen in both structures but in the G6P-bound structure, a new sulphate molecule now occupies the phosphate-binding site. As discussed below, it is possible that these peaks of density correspond instead to a molecule of G6P bound with low occupancy.

For molecule A, the contacts between both forms of G6P and the active site residues are depicted in Figure 3(b) and (c). The phosphate group is positioned by the same cluster of threonine residues, serine residues and main-chain amide groups as described above for E4P. Other interactions, however, depend on the conformation of the ligand. The most striking of these concerns the different positions of the C1–C2 region of the substrate. In the ring form, this region of the substrate is near His388, whereas in the straight-chain form it is positioned on the opposite site of the active site in a pocket formed by Glu511, Gly271, Arg272 and Glu357. In this position, the O^2 atom of the carboxyl group of Glu357 lies approximately equidistant between C1 and C2. Moreover, in straight-chain form, the C1 hydroxyl group contacts Glu357 and both the main-chain amide and side-chain guanidinium group of Arg272, but the same oxygen atom in the ring form is located some 6.9 Å away on the other side of the active site, where it is tethered by Lys518. When the ring form is present, a water molecule instead occupies the same position as O1 in the straight-chain form. These two distinct binding modes for G6P are direct evidence of a large shift in the conformation of the substrate that occurs after the ring-opening step (discussed below). Within the ring form itself, O1 appears to occupy two positions and these could correspond to the two anomers of the substrate. The oxygen atom in the α-like position is close to a water molecule, and in the β-like position is near the N^6 atom of Lys518. The position of the C2 hydroxyl group also differs between the two binding modes: it hydrogen bonds with a water molecule in the straight-chain, but in the ring form contacts Glu357. Continuing along the substrate chain, the C3 hydroxyl group in the ring form occupies the same position at C3 in the straight form and is within hydrogen bonding distance of Glu357. In the straight-chain form, however, this group hydrogen bonds instead with the carbonyl group of His388. Thereafter, the remaining atoms of the substrate converge. The position of the C4 hydroxyl group in both forms is essentially the same and makes potential hydrogen bonds with the main-chain amide group of Gly158 and a water molecule. Likewise, the C5 hydroxyl group in the open-chain form and its ring oxygen counterpart occupy the same position. The binding of G6P to the active site of molecule A produces almost no shifts in the positions of the amino acid residues surrounding the substrate molecule compared to the same subunit in the substrate-free structure (not shown). This is in contrast to the situation in the E4P complex, where the binding of that ligand causes a large movement of cL23 such that both the N^6 atom of Lys518 and N^5 atom of His388 are equidistant from the ring oxygen atom. In the complex with G6P, the N^5 atom of His388 is 2.8 Å from the ring oxygen atom, but the N^6 atom of Lys518 remains 4.6 Å away. This has implications for the mechanism of sugar ring opening (discussed below).
Comparison with rabbit PGI structure complexed with fructose-6-phosphate

The structure of mouse PGI in complex with G6P was compared with a published structure of rabbit PGI in complex with ring-form F6P. The two structures superimpose with an rms deviation in all main-chain atoms of 0.47 Å (molecule A of mouse PGI versus molecule A of rabbit PGI) and, most importantly, the individual positions of residues in the two active sites overlap very closely (Figure 4). In fact, surprisingly, most of the divergence between the active sites is in the substrate itself and not the protein structure, due primarily to the altered shape of a five-membered furanose versus a six-membered pyranose ring. Overall, the enzyme contacts made by G6P and F6P, both in the ring form, are quite similar. There is some difference in the position of C6, but the phosphate-binding contacts and the contacts involving the C3 and C4 hydroxyl groups of both G6P and F6P are essentially the same in both structures. The principal differences occur in the C1–C2 regions of the substrates. In essence, the relative positions of...
Mechanism of Sugar Ring Opening

Figure 3. The structure of mouse PGI in complex with glucose 6-phosphate at 1.6 Å resolution. (a) A stereo picture of the active site region of molecule A, showing unbiased |Fo| - |Fc| electron density corresponding to G6P, contoured at 1σ and coloured blue. The ring form of G6P is shown as cyan bonds and that of the straight chain as green bonds. Water molecules are represented as red spheres and potential hydrogen bonds are shown as broken lines. The proximity of Glu357 to carbon atoms 1 and 2 of G6P is denoted by broken lines. This Figure was prepared using Pymol (http://pymol.sourceforge.net/). (b) The contacts between PGI and the ring form of G6P. The distance between specific atoms are shown as broken lines and the distances are in Å. (c) Contacts between PGI and the straight-chain form of G6P. the C1 and C2 hydroxyl groups are reversed. The C2 hydroxyl group of G6P and C1 hydroxyl group of F6P occupy similar positions, and both are within hydrogen-bonding distance of Glu357. Likewise, C1 of G6P is closer to C2 of F6P than C1. The respective ring oxygen atoms are positioned differently, but both are within hydrogen-bonding distance of His388. A water molecule in the rPGI-F6P complex occupies the same position as the C1 hydroxyl group in the open form of G6P. A water molecule occupies this position also when the ring form of G6P is present in the active site (see above).

Discussion

We have determined the crystal structure of mouse PGI in a sulphate-bound "native" form, bound to the inhibitor erythrose 4-phosphate, and in complex with its substrate molecule glucose-6-phosphate at 1.7 Å resolution. While the structure of rabbit PGI in complex with the cyclic form of the substrate, fructose-6-phosphate, is known, the first structure of PGI bound with its other substrate, glucose 6-phosphate. In particular, the unique view of PGI of interacting with G6P, in both the ring and the straight-chain forms, provides new information regarding its enzyme mechanism.

Implications for catalytic mechanism

Phosphoglucose isomerase interconverts glucose 6-phosphate and fructose 6-phosphate. In solution, both of these substrates exist predominantly in their cyclic hemiacetal or hemiketal forms; hence, it is assumed that PGI catalyzes two discrete activities; ring opening/closing, and the aldose/ketose isomerization itself. Crystal structures have implicated Glu357 as the base catalyst in the isomerization reaction, and His388 as an acid catalyst in ring opening. Mutational data of PGI from Bacillus stearothermophilus support a critical role for both of these residues in catalysis.

Although His388 appears to be involved intimately in the ring-opening mechanism, another residue nearby is Lys518. In fact, in crystal
Mechanism of Sugar Ring Opening

A comprehensive reaction mechanism

The new insight provided by the G6P-bound structure and, in particular, the role of Lys518 and the rotation of the substrate after ring opening, allows a detailed and comprehensive reaction scheme for PGI to be presented (Figure 5). After binding as a hemiacetal, the sugar ring of glucose 6-phosphate is opened in a concerted "push-pull" mechanism mediated by His388 and Lys518, in which the histidine residue protonates the C5 oxygen atom and the lysine residue simultaneously deprotonates the C1 hydroxyl group, forming the open-chain aldose. Rotation of the substrate about its C3-C4 bond then transports the C1-C2 region to a pocket formed by Gln511, Gly271, Arg272 and Glu357, where isomerization takes place. In this step, Glu357 abstracts the C2 proton and the resulting flow of electrons generates a double bond between C1 and C2, thus forming a cis-enediolate intermediate. The negative charge on this intermediate is stabilized by the positive charge of Arg272 and can resonate between the O1 and O2 positions. The outcome of the reaction depends on where Glu357 re-donates its proton. If it goes back to C2, then G6P is reformer, but if it is donated instead to C1, the C2 hydroxyl group loses a proton to form a ketone, and the open-chain ketose, F6P, is the product. As a prelude to ring closure, the C3-C4 bond rotates again to bring the C2 carbonyl group to within bonding distance of O5 and close to Lys518. Ring closure is the reverse of the push-pull ring-opening mechanism. Lys518 donates a proton to the C2 carbonyl oxygen atom and His388, now acting as a base, deprotonates the C5 oxygen atom, generating a short lived oxanyon that attacks the electron-deficient carbon centre at C2, thus forming the hemiketal product.

This mechanism fits well with all the structural evidence, but is less easy to reconcile with the pH
profile of the reaction catalyzed by PGI. This shows two transitions, at approximately pH 6.7 and pH 9.3; prior to the publication of any crystal structure of PGI, these were attributed to a histidine residue and a lysine residue, respectively. Similar pKₐ values have been measured in PGI from different sources including yeast, rabbit and trypanosomes. In agreement, our mechanism shows
the ionization of both a histidine residue and a lysine residue but, in apparent disagreement, that also of a third group, namely Glu357. Worse still, neither of the observed pK_a values fits well with the ionization of a glutamic acid residue, whose unperturbed pK_a is close to 4, and yet it is clear from the crystal structures of PGI that Glu357 is the base catalyst for isomerization. The best explanation is that the protein structure surrounding Glu357 perturbs the pK_a of this group upward in the native structure, likewise the 3_6 helix carrying His388 has not moved significantly, and 3_10 remains in its native position, further away from the active site. The same view as molecule A is seen in the complex of rabbit PGI with F6P in its ring form. The movement of 3_10 cannot be constrained by crystal packing interactions, because it has shifted in the complex with E4P. One explanation for this configuration is that 3_10 shifts toward the active site only when the substrate is present in the straight-chain form, i.e. after ring opening and after rotation of the C3-C4 bond. However, this is unlikely because the complex of PGI with G6P contains a mixture of substrate in both ring and straight-chain forms. Another explanation is that the movement in 3_10 occurs only when PGI binds inhibitors (e.g. E4P as noted above) and does not occur during the normal catalytic reaction involving F6P or G6P. To prove or disprove this hypothesis would require a structure of PGI in complex with substrate present wholly in the straight-chain form. Nonetheless, it is interesting to note the lack of structural difference between mouse PGI in complex with G6P and rabbit PGI in complex with ring-form F6P (Figure 4), which suggests that perhaps the conformational changes in PGI arise directly from the binding of substrate but, once bound, the only movements associated with catalysis are of the substrate itself.

**Why conventional PGIs do not catalyse a phosphomannose isomerase activity**

One of the more exquisite features of PGI is its ability to isomerize glucose 6-phosphate to fructose 6-phosphate but not mannose 6-phosphate to the same product. A very slight phosphomannose (PMI) activity has been measured in the yeast enzyme, but at a non-physiological rate. G6P and M6P are epimers and differ only in the configuration at C2. Interestingly, PGI can bind M6P and catalyzes the interconversion of its anomeric forms. How then does PGI prevent the isomerisation of M6P to F6P? The structure of mouse PGI in complex with glucose 6-phosphate in both the straight-chain form and the ring form provides an ideal framework with which to answer this question. As this structure shows, after the ring-opening step, a rotation about the C3-C4 bond brings the C1-C2 region of G6P (or F6P) into proximity with the base catalyst, Glu357. We modeled the straight-chain form of M6P into the active site of PGI using the straight-chain form of G6P as a template. M6P could be positioned so that the proton to be
Figure 6. The structural basis for the specificity of PGI for glucose 6-phosphate over mannose 6-phosphate. In this stereoview, (A) shows the active-site region of mouse PGI in complex with the straight-chain form of G6P (coloured orange). The model of straight-chain mannose 6-phosphate (coloured green) is shown superimposed onto G6P such that the proton at C2 is directed toward Glu357. To form F6P, any proton abstracted from C2 of M6P must be donated back to C1. For C1 to reach Glu357, however, requires a rotation of M6P about its C2–C3 bond and this leads to a steric clash of the C1 hydroxyl group of M6P with Gln511, as shown in (B).

abstraction from C2 was pointing toward the base catalyst, Glu357, suggesting that, at least, abstraction of this proton is possible in PGI. But, in order for the proton to be donated back to C1, M6P must undergo rotation about the C2–C3 bond to position C1 near Glu357. Rotation in one direction is prevented by a clash between the C2 hydroxyl group and Glu357 (clockwise about the C3–C2 bond, viewed from C3). Rotation in the opposite direction is impeded due to a steric clash between C1–O1 and the side-chain of Gln511 (Figure 6). This glutamine residue is highly conserved within the PGI family of enzymes and lies immediately adjacent to Glu357. If O1 were moved to a position trans to O2 through rotation about C1–C2, rotation of C2–C3 would be prevented by a clash with Gln353 (not shown). Thus, it seems likely that Gln511 and, to a lesser extent, Gln353, constitutes the structural basis for the specificity of PGI for G6P over M6P. Distantly related members of the PGI superfamily in Archaeal species such as Aeropyrum pernix and Thermoplasma acidophilum function as bifunctional PGI/PMI enzymes. It will be interesting to determine whether the active sites of these enzymes permit such a rotation about C2–C3 and so isomerize M6P to F6P.

Materials and Methods

Protein expression and purification

A full-length mouse cDNA was identified by searching the NCBI database of EST clones, using the original sequence entry (Genbank accession no. M14220, mouse neuroleukin). A cDNA corresponding to Genbank accession number A1037338 was obtained from the IMAGE Consortium, and a 1.7 kb DNA fragment encoding only the open reading frame was prepared by PCR as described for rabbit PGI. Flanking PCR primers changed the 5′ end to a methionine start codon within a
unique NdeI restriction enzyme recognition site, and the normal stop codon was replaced by six histidine codons followed by a new UAA stop codon plus an EcoRI recognition site. The PCR primers were used to amplify the open reading frame with a minimal cycle number and high-fidelity Vent DNA polymerase (NE BioLabs Inc). The amplified DNA was subcloned into the bacterial expression vector pET5a as an NdeI-to-EcoRI fragment and expressed in Escherichia coli BL21DE3pLysS (Stratagene Inc). Bacteria were induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for three hours at 30 °C. Cell pellets were collected by low-speed centrifugation, lysed by sonication without protease inhibitors, and clarified by high-speed centrifugation. Soluble supernatants were bound to Ni-NTA agarose (Qiagen Inc.) and washed and eluted according to the manufacturer’s standard protocol. The protein eluting in 0.25 M imidazole was >95% homogeneous as estimated from Coomassie blue staining of the protein on denaturing, reducing 12.5% (w/v) polyacrylamide gels. Yields were 25–50 mg per liter of bacterial culture. The purified protein was concentrated to approximately 4 mg/ml and equilibrated with phosphate-buffered standard saline using Centricon-30 ultrafiltration (Amicon Inc).

When the inserted DNA within the expression vector was sequenced, two differences were noted from the canonical sequence (Genbank accession no. M14220) of mouse neuroleukin. The first was D94N (codon at nucleotides 315–317 changed from GAT to GTT) to an alanine site. The first change corresponds to a common polymorphism that defines the Gpi-Sb alleles, which are used as a routine electrophoretic method for the identification of Gpi-Sa versus Gpi-Sb. It was noted that the Gpi-Sb is purified from rabbit, the N-terminal contains a methionine residue at the N terminus, neither of these is visible in the electron density map, and so in accordance with the native protein, the final structure is numbered 1-537, starting at Ala1.

Crystallization and data collection

The protein was subjected to crystallization trials using the hanging-drop method. Crystals of mPGI were cryo-frozen by passing through a stabilizing solution of 1.9 M ammonium sulphate, 100 mM Tris-HCl (pH 8.5), with glycerol added to 30% (v/v) final concentration as cryoprotectant. Diffraction data were collected on a RAXIS IV+ + imaging plate system mounted on an RU-H3R X-ray generator operating at 50 kV and 100 mA and fitted with Osmic Confocal Optics (Rigaku/MSC, The Woodlands, TX). The crystal-to-detector distance was 100 mm and data were collected in 0.5° oscillations with an exposure time of eight minutes per frame. To introduce substrate or inhibitor molecules, the crystals were soaked in stabilizing solutions containing the ligand. The complex with glucose 6-phosphate arose following a soak in fructose 6-phosphate. Molarities of ligands and the soaking times were varied to ensure maximal occupancy of the active site, as judged by difference Fourier maps. To refine the model against this data set. The crystals were cryo-protected as before, using 30% glycerol. Typically, 200° of data were collected to obtain essentially complete data sets. The data set collected from a crystal soaked in erythrose 4-phosphate was collected on the home source (as above) and processed with CrystalClear. The data collected from the crystal soaked in fructose 6-phosphate were collected at beamline 22 at the Advanced Photon Source. For this experiment, the crystal-to-plate distance was 130 mm, the exposure time was one second and 360° data were acquired using a MAR225 CCD system. These data were processed using d*Trek.

Structure determination

The structure of mouse PGI was solved by molecular replacement using a dimer of rabbit PGI1 as a search model. The calculation was performed using MOLREP and used data extending to 3 Å resolution. A single clear solution arose with an R-factor of 37.6% and correlation coefficient of 0.65. This solution was then applied to a homology model of mouse PGI, which had been generated from the rabbit structure using the Swiss-Model Server. After an initial refinement using XPLOR, the model was improved by iterative cycles of manual rebuilding, using O and crystallographic refinement with REFMAC. 5% of reflections were set aside from the refinement and used to calculate the Rmerge. Molecules of water, glycerol, sulphate and β-mercaptoethanol were added if visible in both IFo-IFcl and 2(IFo-IFcl) electron density maps and if within hydrogen bonding distance of at least two other atoms in the structure. Water modeling was performed using ARP/WARP. When PGI is purified from rabbit, the N-terminal residue is alanine. Although this construct of PGI contains a methionine residue at the N terminus, neither of these is visible in the electron density map, and so in accordance with the native protein, the final structure is numbered 1-537, starting at Ala1.

For the ligand-bound structures, the starting model for refinement was the sulphate-bound native structure. After initial refinement, each ligand was modeled into its respective IFo-IFcl density and thereafter the procedure for refinement was the same as for the native structure. To generate unbiased electron density for pictures showing the binding of ligands to the active site of PGI, an additional round of refinement was performed in which the occupancies of those ligands was set to zero. The O program was used to model mannose 6-phosphate into mouse PGI and to perform rotations of the molecule within the active site.

Protein Data Bank accession codes

The coordinates and structure factors for each structure have been submitted to the RCSB Protein Data Bank (PDB): code Native, 1UU0; E4P, 1U0F, F6P, 1U0G.

Acknowledgements

J.T.G.S. is supported by a grant from the National Science Foundation (EPS-0132573) and E.M.Z. is supported by a cross-training grant from the NIH (R25GM067084). This research was supported also by grants from the U.S. Army (DAMD17-98-1-8245 and DAMD17-02-1-0586) to J.M.C. We extend our gratitude to Klaus Schnackerz, whose gift of 5-phosphoarabinonate has greatly assisted our ongoing studies of PGI. Data were collected at the Southeast Regional Collaborative Access Team...
(SER-CAT) 22-ID beamline at the Advanced Photon Source, Argonne National Laboratory. Supporting institutions may be found at www.ser-cat.org/members.html. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences, under contract no. W-31-109-Eng-38.

References


*Edited by I. Wilson*

(Received 26 May 2004; received in revised form 19 July 2004; accepted 23 July 2004)